Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Drug Information

Target Indication

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Clinical Trial

Last updated: 6/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

APRE

Aprea Therapeutics, Inc.

Related Pipeline

MDS

High-grade Serous Ovarian Cancer

Acute Myeloid Leukemia or Myelodysplastic Syndromes

Advanced Solid Tumor

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts